Substance P
Evidence: CCognitive / Neuro
Evidence Snapshot
What this grade covers
Exact Substance P has extensive direct human experimental pharmacology, including randomized studies of headache, sleep/mood, neuroendocrine responses, vasodilation, and cutaneous inflammation. This does not establish therapeutic benefit from administering Substance P.
Regulatory Context
Substance P is an endogenous human peptide studied extensively in controlled human experimental settings; it is not an FDA-approved drug. No subject-specific FDA regulatory action has been identified in the current source set, and the absence of FDA approval does not itself indicate that Substance P is unsafe.
Research Takeaway
Substance P is a distinct mature tachykinin produced from the human TAC1 precursor, which can also produce Neurokinin A, Neuropeptide K, and Neuropeptide gamma.
Evidence boundary: Shared TAC1 origin does not make those other mature peptides interchangeable with Substance P.
See all 7 evidence claims →Quick Summary
Substance P is a mature tachykinin peptide produced from the human TAC1 precursor, which also gives rise to the distinct peptides Neurokinin A, Neuropeptide K, and Neuropeptide gamma. Substance P has one of the most extensive direct-human experimental pharmacology records of any Batch 13 subject: controlled, randomized studies have administered it intravenously, intra-arterially, and intradermally, documenting effects on headache/migraine provocation, mood and sleep, neuroendocrine hormone release, vascular tone, and cutaneous inflammation. This is substantial human pharmacology evidence; it does not establish that administering Substance P provides any therapeutic benefit.
Mechanism & Research Overview
Controlled human studies support roles for Substance P in nociceptive/headache signaling (a 2025 randomized trial found intravenous Substance P induced headache in 15 of 21 healthy adults versus 2 of 21 on placebo), neurogenic cutaneous inflammation (intradermal Substance P produces flare, wheal, and itch mediated largely by histamine release), vascular tone (forearm vasodilation shown to be mediated by the NK1 receptor), and neuroendocrine regulation (dose-dependent increases in growth hormone, ACTH, and cortisol). Substance P also altered sleep and mood measures in a controlled nighttime infusion study. NK1-receptor antagonist/agonist drug findings can help interpret this signaling only when exact Substance P's own role is directly established in the same experiment.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Substance P is a distinct mature tachykinin produced from the human TAC1 precursor, which can also produce Neurokinin A, Neuropeptide K, and Neuropeptide gamma.
Does not establish
Evidence boundary: Shared TAC1 origin does not make those other mature peptides interchangeable with Substance P.
Sources: TAC1 - Protachykinin-1 - Homo sapiens (Human)
Supported
Exact Substance P has been directly administered in controlled human studies and produces measurable neurological, vascular, endocrine, and cutaneous effects.
Does not establish
Evidence boundary: Human pharmacology does not establish therapeutic benefit.
Sources: Effects of substance P on headache induction and arterial dilation in healthy adults; Effects of substance P on memory and mood in healthy male subjects; Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men; Intravenously infused substance P enhances basal and growth hormone releasing hormone-stimulated GH secretion in normal men; Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate; Flare and itch induced by substance P in human skin; Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man
Supported
Human studies support roles for Substance P in nociceptive/headache signaling, neurogenic inflammation, vascular responses, and neuroendocrine regulation.
Does not establish
Evidence boundary: These are experimental mechanistic findings and should not be reframed as treatment indications.
Sources: Effects of substance P on headache induction and arterial dilation in healthy adults; Intravenously infused substance P enhances basal and growth hormone releasing hormone-stimulated GH secretion in normal men; Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate; Flare and itch induced by substance P in human skin; Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man
Supported
In a 2025 randomized placebo-controlled crossover study, intravenous Substance P induced headache substantially more often than placebo in healthy adults.
Does not establish
Evidence boundary: This demonstrates headache-provoking pharmacology, not a benefit of Substance P administration.
Sources: Effects of substance P on headache induction and arterial dilation in healthy adults
Supported
NK1-receptor drug studies can help interpret Substance P signaling only when the role of exact Substance P is directly established in the experiment.
Does not establish
Evidence boundary: NK1 antagonist or agonist efficacy cannot be transferred to Substance P itself.
Supported
Controlled human Substance P administration has produced headache, mood/sleep changes, endocrine responses, vasodilation, and local inflammatory reactions depending on route and model.
Does not establish
Evidence boundary: These small experimental studies do not establish chronic-use safety, recommended dosing, or safety of vendor formulations.
Sources: Effects of substance P on headache induction and arterial dilation in healthy adults; Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men; Intravenously infused substance P enhances basal and growth hormone releasing hormone-stimulated GH secretion in normal men; Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate; Flare and itch induced by substance P in human skin; Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man
Supported
No therapeutic efficacy claim is frozen for Substance P in Stage 3A.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
A 2025 randomized placebo-controlled crossover study found intravenous Substance P induced headache in 15/21 healthy adults versus 2/21 on placebo.Safety Consideration
Controlled studies found Substance P increased ACTH/cortisol and growth hormone secretion in a dose-dependent way, and worsened mood and altered sleep measures in a nighttime infusion study.Safety Consideration
Intradermal Substance P produces flare, wheal, and itch in human skin, largely mediated by histamine release.Safety Consideration
All evidence comes from small, short-duration experimental studies using controlled research routes and doses; safety of chronic, non-study, or vendor-supplied use is not established.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effects of substance P on headache induction and arterial dilation in healthy adults (2025):
- Effects of substance P on memory and mood in healthy male subjects (2007):
- Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men (2002):
- Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man (1999):
- Intravenously infused substance P enhances basal and growth hormone releasing hormone-stimulated GH secretion in normal men (1992):
- Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate (1992):
- Flare and itch induced by substance P in human skin (1978):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of substance P on headache induction and arterial dilation in healthy adults | 2025 | 21 healthy adults; double-blind placebo-controlled randomized two-way crossover | Headache occurred in 15/21 after Substance P versus 2/21 after placebo, with higher headache-intensity AUC and vascular measurements assessed. | ||
| Effects of substance P on memory and mood in healthy male subjects | 2007 | 13 healthy young men; double-blind randomized crossover IV SP vs placebo | Direct human CNS/behavioral experimental study evaluating memory and mood after Substance P infusion. | ||
| Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men | 2002 | 12 healthy young men; double-blind randomized crossover nighttime IV SP vs saline | Substance P worsened mood, altered sleep measures, and changed cortisol/TSH-related neuroendocrine measures in this controlled model. | ||
| Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man | 1999 | 16 healthy male volunteers; randomized double-blind placebo-controlled crossover NK1 antagonist with intra-arterial Substance P | Substance P-induced vasodilation in human forearm was strongly inhibited by an NK1 receptor antagonist, supporting NK1 mediation. | ||
| Intravenously infused substance P enhances basal and growth hormone releasing hormone-stimulated GH secretion in normal men | 1992 | Small randomized clinical physiology experiments in healthy men | Higher-dose SP infusion increased GH secretion and enhanced GH response to GHRH. | ||
| Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate | 1992 | Healthy men; randomized SP vs saline dose experiments | Higher SP doses increased ACTH/cortisol in a dose-dependent fashion. | ||
| Flare and itch induced by substance P in human skin | 1978 | Controlled intradermal synthetic Substance P in humans | Intradermal SP produced flare, wheal, and itch, largely mediated by histamine release in human skin. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| TAC1 - Protachykinin-1 - Homo sapiens (Human) | Homo sapiens curated identity record | Human TAC1 precursor; documents Substance P, Neurokinin A, Neuropeptide K, Neuropeptide gamma as distinct chains. | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-24.
Follow research updates for Substance P
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.